{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-187318","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2023-07-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.916549+00:00","generated_at":"2026-06-13T08:15:08.605348+00:00","sec_items":["1.01","5.01","5.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Frequency Therapeutics to merge with Korro Bio in reverse merger; Korro valued at ~$325.6M","bullets":["Korro Bio equity valued at ~$325.6M; Frequency equity based on net cash at closing.","Concurrent PIPE financing of ~$117M from accredited investors.","Combined company board: 4 from Korro, 1 from Frequency, 2 independent.","~98% of Korro stockholders and ~11.7% of Frequency stockholders support merger.","Frequency stockholders to receive CVRs for potential proceeds from MS asset sale."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-187318","json":"https://secwatch.observer/filing/0001193125-23-187318.json","markdown":"https://secwatch.observer/filing/0001193125-23-187318.md","text":"https://secwatch.observer/filing/0001193125-23-187318.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523187318/0001193125-23-187318-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523187318/d651936d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T08:15:08.605348+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"50be3de24b031cfae7c1bd8bbf5c53bf96bf5f97","claim":"Korro Bio, Inc. entered into Agreement and Plan of Merger with Frequency Therapeutics, Inc., Frequency Merger Sub, Inc. valued at approximately $325.6 million (effective 2023-07-14).","evidence_excerpt":"On July 14, 2023, Frequency Therapeutics, Inc. (“ Frequency ” or the “ Company ”), Frequency Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“ Merger Sub ”), and Korro Bio, Inc., a Delaware corporation (“ Korro Bio ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523187318/0001193125-23-187318-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Frequency Therapeutics, Inc., Frequency Merger Sub, Inc."},{"label":"Value","value":"approximately $325.6 million"},{"label":"Effective","value":"2023-07-14"}],"fact_type":"material_agreement"},{"claim_id":"9d6f1927cb4fc60e8bf9b6b194e30eff513ee043","claim":"Korro Bio, Inc. entered into Subscription Agreements with certain accredited investors valued at approximately $117 million (effective 2023-07-14).","evidence_excerpt":"On July 14, 2023, Korro Bio entered into subscription agreements with certain accredited investors for the Concurrent Financing with expected gross proceeds to Korro Bio of approximately $117 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312523187318/0001193125-23-187318-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"approximately $117 million"},{"label":"Effective","value":"2023-07-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}